What is claimed is:

1. A compound or a pharmaceutically acceptable salt represented by Formula (I):



(I)

wherein:

 is a nitrogen-containing 3-to 10-membered heterocyclyl ring optionally substituted by one to three substituents selected from R^7;

R^1 is:

i) R^4;

ii) a group having a formula $-SO_n-T-(CR^9R^{10})_bR^3$, $-SO_n-(CR^9R^{10})_b-T-R^3$, $-SO_nNR^4C(O)R^3$, wherein n or b are, independently, 0, 1 or 2 and T is a bond, -O-, $-NR^4-$, or –S-; or

iii) a group having a formula $-C(=O)-R^3$, $-C(=O)-HC=CH-R^3$, $-C(=O)NHR^3$, $-C(=O)NR^5R^6$, or $-C(=S)R^3$;

R^2 is (C_1-C_8)alkyl, (C_3-C_{10})cycloalkyl, $-O-(C_1-C_8)$alkyl, (C_6-C_{10})aryl, or 4-to 10-membered heterocyclyl, optionally substituted by one to four substituents selected from R^7;

wherein R^3 is OH, F, Cl, Br, I, CN, CF_3, NO_2, $-(CH_2)_dNR^5R^6$, $-O-R^4$, $-SO_p-R^4$ wherein p is 0,1, or 2, $-PO_p-R^4$ wherein p is 3 or 4, (C_1-C_8)alkyl, $-(CH_2)_d(C_3-C_{13})$cycloalkyl, $-O-(C_1-C_8)$alkyl, $-(CH_2)_d-(C_6-C_{10})$aryl, $-(CH_2)_d-$(4-to 10-membered heterocyclyl), (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-SO_q-NR^5R^6$, wherein d is an integer 0 to 6 and q is 1 or 2, $-C(=O)-R^8$, $-C(O)OR^8$, $-C(=O)-NR^5R^6$;

wherein R^4 is selected from the group consisting of hydrogen, (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-O-(C_1-C_8)$alkyl, $-(CH_2)_e-(C_3-C_{13})$cycloalkyl, $-(CH_2)_e-(C_6-C_{10})$aryl, or $-(CH_2)_e-$(4-to10-membered heterocyclyl);

wherein R^5 is independently H or (C_1-C_8)alkyl;

wherein R^6 is selected from the group consisting of $-Si(CH_3)_3$, (C_1-C_8)alkyl, $-O-(C_1-C_8)$alkyl, $-CH_2-(C=O)-O-(C_1-C_8)$alkyl, (C_3-C_{10})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl; or R^5 and R^6 when attached to the same nitrogen may optionally be taken together with the same nitrogen to form a 5-to 10-membered heterocyclyl ring;

wherein each (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-O-(C_1-C_8)$alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl, in the above definitions of said R^3, R^4, R^5, R^6 and R^8 may be optionally substituted by one to four R^7 substituents;

wherein R^7 is (C_1-C_8)alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, 4-to 10-membered heterocyclyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, $-O-(C_1-C_8)$alkyl, H, OH, F, Cl, Br, I, CN, CF_3,

amidino, -C(O)OR^9, -C(O)R^9, -SR^9, -SO$_2$R^9, -NO$_2$, -NR^{9}C(O)R^{10}, -OC(O)R^9-aryl, -NSO$_2$R^9, -SC(O)R^9, -NC(=S)NR^{9}R^{10}, -O-N=CR^9, -N=N-R^9, -C(O)NR^{9}R^{10}, -(CH$_2$)$_t$-NR^{9}R^{10}, 2- to 10-membered heteroalkyl, 3- to 10- membered heteroalkenyl, 3- to 10- membered heteroalkynyl, -(CH$_2$)$_t$(C$_6$-C$_{10}$ aryl), -(CH$_2$)$_t$(4- to 10- membered heterocyclic), -(2- to 10- membered heteroalkyl)-(C$_6$-C$_{10}$ aryl), -(2- to 10- membered heteroalkyl)-(4- to 10- membered heterocyclyl), -(CH$_2$)$_t$O(CH$_2$)$_u$OR^9, and -(CH$_2$)$_t$OR^9, wherein t is an integer from 0 to 6 and u is an integer from 2 to 6, H or (C$_1$-C$_8$)alkyl;

wherein R^8 is selected from the group consisting of H, OH, CF$_3$, (C$_1$-C$_8$)alkyl, (C$_2$-C$_6$)alkenyl, (C$_2$-C$_6$)alkynyl, -O-(C$_1$-C$_8$)alkyl, (C$_3$-C$_{10}$)cycloalkyl, -O-(C$_3$-C$_{10}$)cycloalkyl, 4-to 10-membered heterocyclyl, and 4-to 10-membered –O-heterocyclyl;

wherein each R^9 and R^{10} are independently selected from the group consisting of H, (C$_1$-C$_8$)alkyl, (C$_1$-C$_8$)alkoxyl, -CH$_2$-(C=O)-O-(C$_1$-C$_8$)alkyl, (C$_3$-C$_{10}$)cycloalkyl, (C$_6$-C$_{10}$)aryl, and 4-to 10-membered heterocyclyl; or R^9 and R^{10} when together attached to the same N, may optionally be taken together with the same nitrogen to form a 5-to 10-membered heterocyclyl ring; with the proviso that where R^9 and R^{10} are both attached to the same nitrogen, then R^9 and R^{10} are not both bonded to the nitrogen directly through an oxygen;

wherein any of the ring members of each (C$_3$-C$_{13}$)cycloalkyl or 4-to 10-membered heterocyclyl in R^3, R^4, R^6, R^7, R^8, R^9 and R^{10} may be optionally substituted with an oxo (=O) and wherein any of the (C$_1$-C$_8$)alkyl, (C$_2$-C$_6$)alkenyl, (C$_2$-C$_6$)alkynyl, -O-(C$_1$-C$_8$)alkyl, (C$_3$-C$_{13}$)cycloalkyl, (C$_6$-C$_{10}$)aryl, and 4-to 10-membered heterocyclyl in R^7, R^9 and R^{10} may be independently further substituted with at least one OH, F, CL, Br, I, CN, CF$_3$, NO$_2$, -(C$_1$-C$_8$)alkyl, -(C$_1$-C$_8$) alkoxyl, COH, or C(O)-(C$_1$-C$_8$alkyl).

2. A compound or salt according to claim 1, wherein R^1 is R^4, optionally substituted by one or more R^9 substituents.

3. A compound or pharmaceutically acceptable salt represented by Formula (I):



(I)

wherein:

 is a nitrogen-containing 3-to 10-membered heterocyclyl ring optionally substituted by one to three substituents selected from R^7;

R^1 is a group having a formula $-SO_n-T-(CR^9R^{10})_bR^3$, $-SO_n-(CR^9R^{10})_b-T-R^3$, $-SO_nNR^4C(O)R^3$, wherein n or b are, independently, 0, 1 or 2 and T is a bond, -O-, $-NR^4-$, or –S-; or

R^2 is (C_1-C_8)alkyl, (C_3-C_{10})cycloalkyl, $-O-(C_1-C_8)$alkyl, (C_6-C_{10})aryl, or 4-to 10-membered heterocyclyl, optionally substituted by one to four substituents selected from R^7;

wherein R^3 is OH, F, Cl, Br, I, CN, CF_3, NO_2, $-NR^5R^6$, $-O-R^4$, $-SO_p-R^4$ wherein p is 0,1, or 2, $-PO_p-R^4$ wherein p is 3 or 4, (C_1-C_8)alkyl, $-(CH_2)_d(C_3-C_{13})$cycloalkyl, $-O-(C_1-C_8)$alkyl, $-(CH_2)_d-(C_6-C_{10})$aryl, $-(CH_2)_d-$(4-to 10-membered heterocyclyl), (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-SO_q-NR^5R^6$, wherein d is an integer 0 to 6 and q is 1 or 2, $-C(=O)-R^8$, $-C(O)OR^8$, or $-C(=O)-NR^5R^6$;

wherein R^4 is each independently selected from the group consisting of hydrogen, (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-O-(C_1-C_8)$alkyl, $-(CH_2)_e-(C_3-C_{13})$cycloalkyl, $-(CH_2)_e-(C_6-C_{10})$aryl, or $-(CH_2)_e-$(4-to10-membered heterocyclyl);

wherein R^5 is independently H or (C_1-C_8)alkyl;

wherein R^6 is selected from the group consisting of $-Si(CH_3)_3$, (C_1-C_8)alkyl, $-O-(C_1-C_8)$alkyl, $-CH_2-(C=O)-O-(C_1-C_8)$alkyl, (C_3-C_{10})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl; or R^5 and R^6 when attached to the same nitrogen may optionally be taken together with the same nitrogen to form a 5-to 10-membered heterocyclyl ring;

wherein each (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-O-(C_1-C_8)$alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl, in the above definitions of said R^3, R^4, R^5, R^6 and R^8 may be optionally substituted by one to four R^7 substituents;

wherein R^7 is (C_1-C_8)alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, 4-to 10-membered heterocyclyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, $-O-(C_1-C_8)$alkyl, H, OH, F, Cl, Br, I, CN, CF_3, amidino, $-C(O)OR^9$, $-C(O)R^9$, $-SR^9$, $-SO_2R^9$, $-NO_2$, $-NR^9C(O)R^{10}$, $-OC(O)R^9$-aryl, $-NSO_2R^9$, $-SC(O)R^9$, $-NC(=S)NR^9R^{10}$, $-O-N=CR^9$, $-N=N-R^9$, $-C(O)NR^9R^{10}$, $-(CH_2)_t-NR^9R^{10}$, 2 to 10 membered heteroalkyl, 3- to 10- membered heteroalkenyl, 3- to 10- membered heteroalkynyl, $-(CH_2)_t(C_6-C_{10}$ aryl), $-(CH_2)_t$(4 to 10 membered heterocyclic), -(2 to 10 membered heteroalkyl)-(C_6-C_{10} aryl), -(2 to 10 membered heteroalkyl)-(4 to 10 membered heterocyclyl), $-(CH_2)_tO(CH_2)_uOR^9$, and $-(CH_2)_tOR^9$, wherein t is an integer from 0 to 6 and u is an integer from 2 to 6, H or (C_1-C_8)alkyl;

wherein R^8 is selected from the group consisting of H, OH, CF_3, (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, $-O-(C_1-C_8)$alkyl, (C_3-C_{10})cycloalkyl, $-O-(C_3-C_{10})$cycloalkyl, 4-to 10-membered heterocyclyl, and 4-to 10-membered –O-heterocyclyl;

wherein each R^9 and R^{10} are independently selected from the group consisting of H, (C_1-C_8)alkyl, (C_1-C_8)alkoxyl, $-CH_2-(C=O)-O-(C_1-C_8)$alkyl, (C_3-C_{10})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl; or R^9 and R^{10} when together attached to the same N, may optionally be taken together with the same nitrogen to form a 5-to 10-membered heterocyclyl

ring; with the proviso that where R^9 and R^{10} are both attached to the same nitrogen, then R^9 and R^{10} are not both bonded to the nitrogen directly through an oxygen;

wherein any of the ring members of each $(C_3\text{-}C_{13})$cycloalkyl or 4-to 10-membered heterocyclyl in R^3, R^4, R^6, R^7, R^8, R^9 and R^{10} may be optionally substituted with an oxo (=O) and wherein any of the $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, -O-$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{13})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, and 4-to 10-membered heterocyclyl in R^7, R^9 and R^{10} may be independently further substituted with at least one OH, F, CL, Br, I, CN, CF_3, NO_2, -$(C_1\text{-}C_8)$alkyl, -$(C_1\text{-}C_8)$ alkoxyl, COH, or C(O)-$(C_1\text{-}C_8$alkyl).

4. A compound or pharmaceutically acceptable salt represented by Formula (I):



(I)

wherein:

 is a nitrogen-containing 3-to 10-membered heterocyclyl ring optionally substituted by one to three substituents selected from R^7;

R^1 is a group having a formula –C(=O)-R^3, –C(=O)-HC=CH-R^3, -C(=O)NHR^3, -C(=O)NR^5R^6 or -C(=S)R^3;

R^2 is $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, -O-$(C_1\text{-}C_8)$alkyl, $(C_6\text{-}C_{10})$aryl, or 4-to 10-membered heterocyclyl, optionally substituted by one to four substituents selected from R^7;

wherein R^3 is OH, F, Cl, Br, I, CN, CF_3, NO_2, –NR^5R^6, -O-R^4, -SO_p-R^4 wherein p is 0,1, or 2, -PO_p-R^4 wherein p is 3 or 4, $(C_1\text{-}C_8)$alkyl, -$(CH_2)_d$$(C_3\text{-}C_{13})$cycloalkyl, -O-$(C_1\text{-}C_8)$alkyl, -$(CH_2)_d$-$(C_6\text{-}C_{10})$aryl, -$(CH_2)_d$-(4-to 10-membered heterocyclyl), $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, -SO_q-NR^5R^6, wherein d is an integer 0 to 6 and q is 1 or 2, -C(=O)-R^8, -C(O)OR^8, or -C(=O)-NR^5R^6;

wherein R^4 is each independently selected from the group consisting of hydrogen, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, -O-$(C_1\text{-}C_8)$alkyl, -$(CH_2)_e$-$(C_3\text{-}C_{13})$cycloalkyl, -$(CH_2)_e$-$(C_6\text{-}C_{10})$aryl, or –$(CH_2)_e$-(4-to10-membered heterocyclyl);

wherein R^5 is independently H or $(C_1\text{-}C_8)$alkyl;

wherein R^6 is selected from the group consisting of –$Si(CH_3)_3$, $(C_1\text{-}C_8)$alkyl, -O-$(C_1\text{-}C_8)$alkyl, -CH_2-(C=O)-O-$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, and 4-to 10-membered heterocyclyl; or R^5 and R^6 when attached to the same nitrogen may optionally be taken together with the same nitrogen to form a 5-to 10-membered heterocyclyl ring;

wherein each (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, -O-(C_1-C_8)alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl, in the above definitions of said R^3, R^4, R^5, R^6 and R^8 may be optionally substituted by one to four R^7 substituents;

wherein R^7 is (C_1-C_8)alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, 4-to 10-membered heterocyclyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, -O-(C_1-C_8)alkyl, H, OH, F, Cl, Br, I, CN, CF_3, amidino, $-C(O)OR^9$, $-C(O)R^9$, $-SR^9$, $-SO_2R^9$, $-NO_2$, $-NR^9C(O)R^{10}$, $-OC(O)R^9$-aryl, $-NSO_2R^9$, $-SC(O)R^9$, $-NC(=S)NR^9R^{10}$, -O-N=CR^9, -N=N-R^9, $-C(O)NR^9R^{10}$, $-(CH_2)_t-NR^9R^{10}$, 2- to 10-membered heteroalkyl, 3- to 10- membered heteroalkenyl, 3- to 10- membered heteroalkynyl, $-(CH_2)_t(C_6-C_{10}$ aryl), $-(CH_2)_t$(4 to 10 membered heterocyclic), -(2 to 10 membered heteroalkyl)-(C_6-C_{10} aryl), -(2 to 10 membered heteroalkyl)-(4 to 10 membered heterocyclyl), $-(CH_2)_tO(CH_2)_uOR^9$, and $-(CH_2)_tOR^9$, wherein t is an integer from 0 to 6 and u is an integer from 2 to 6, H or (C_1-C_8)alkyl;

wherein R^8 is selected from the group consisting of H, OH, CF_3, (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, -O-(C_1-C_8)alkyl, (C_3-C_{10})cycloalkyl, -O-(C_3-C_{10})cycloalkyl, 4-to 10-membered heterocyclyl, and 4-to 10-membered –O-heterocyclyl;

wherein each R^9 and R^{10} are independently selected from the group consisting of H, (C_1-C_8)alkyl, (C_1-C_8)alkoxyl, $-CH_2-(C=O)-O-(C_1-C_8)$alkyl, (C_3-C_{10})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl; or R^9 and R^{10} when together attached to the same N, may optionally be taken together with the same nitrogen to form a 5-to 10-membered heterocyclyl ring; with the proviso that where R^9 and R^{10} are both attached to the same nitrogen, then R^9 and R^{10} are not both bonded to the nitrogen directly through an oxygen;

wherein any of the ring members of each (C_3-C_{13})cycloalkyl or 4-to 10-membered heterocyclyl in R^3, R^4, R^6, R^7, R^8, R^9 and R^{10} may be optionally substituted with an oxo (=O) and wherein any of the (C_1-C_8)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, -O-(C_1-C_8)alkyl, (C_3-C_{13})cycloalkyl, (C_6-C_{10})aryl, and 4-to 10-membered heterocyclyl in R^7, R^9 and R^{10} may be independently further substituted with at least one OH, F, CL, Br, I, CN, CF_3, NO_2, -(C_1-C_8)alkyl, -(C_1-C_8) alkoxyl, COH, or C(O)-$(C_1-C_8$alkyl).

5. A compound or salt according to claim 3, wherein R^1 is $-SO_n-T-R^3$, T is as defined above and R^3 is a 4-to 10-membered heterocyclic, optionally substituted by one to four substituents selected from R^7.

6. A compound or salt according to claim 3, wherein T is a bond, R^3 is a 4-to 10-membered heterocyclic and R^7 is an -(C_1-C_8)alkyl.

7. A compound or salt according to claim 4, wherein R^3 is a $-(CH_2)_d(C_3-C_{13})$cycloalkyl, -O-(C_1-C_8)alkyl, $-(CH_2)_d-(C_6-C_{10})$aryl, $-(CH_2)_d$-(4-to 10-membered heterocyclyl), wherein each

R^3 $(C_3$-$C_{10})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4-to 10-membered heterocyclic may be optionally substituted by one to four R^7 substituents.

8. A compound or salt according to claim 3, wherein T is a bond, R^3 is a 5-membered heterocyclyl; and R^7 is $(C_1$-$C_8)$alkyl, $(C_3$-$C_{13})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4-to 10-membered heterocyclyl, -O-$(C_1$-$C_8)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl; wherein each $(C_1$-$C_8)$alkyl, $(C_3$-$C_{13})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4-to 10-membered heterocyclyl, -O-$(C_1$-$C_8)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl may be independently optionally substituted with at least one OH, F, CL, Br, I, CN, CF_3, NO_2, -$(C_1$-$C_8)$alkyl, -$(C_1$-$C_8)$ alkoxyl, COH, or C(O)-$(C_1$-C_8alkyl).

9. A compound or salt according to claim 4, wherein R^3 is a 5-membered heteroaryl; and R^7 is $(C_1$-$C_8)$alkyl, $(C_3$-$C_{10})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4-to 10-membered heterocyclyl, -O-$(C_1$-$C_8)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl; wherein each $(C_1$-$C_8)$alkyl, $(C_3$-$C_{10})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4-to 10-membered heterocyclyl, $(C_1$-$C_8)$alkyl-O-, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl may be optionally substituted with at least one OH, F, CL, Br, I, CN, CF_3, NO_2, -$(C_1$-$C_8)$alkyl, -$(C_1$-$C_8)$ alkoxyl, COH, or C(O)-$(C_1$-C_8alkyl);

10. A compound or salt according to claim 1, wherein R^2 is a 4- to 10- membered heterocyclyl having one or more substituents selected from the group consisting of F, Cl, Br, I.

11. A compound or salt according to claim 3, wherein the group:  is a nitrogen-containing 4-6 membered heterocyclyl ring optionally substituted with $(C_1$-$C_8)$alkyl, $(C_3$-$C_{10})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4- to 10-membered heterocyclyl; and R^2 is a $(C_6$-$C_{10})$aryl, or a 4- to 10-membered heterocyclyl having one or more substituents selected from the group consisting of a F, Cl, Br, I.

12. A compound or salt according to claim 4, wherein the group:  is a nitrogen-containing 4-6 membered heterocyclyl ring optionally substituted by $(C_1$-$C_8)$alkyl, $(C_3$-$C_{10})$cycloalkyl, $(C_6$-$C_{10})$aryl, or 4- to 10-membered heterocyclyl; and R^2 is a $(C_6$-$C_{10})$aryl or 4- to 10-membered heterocyclyl having one or more substituents selected from the group consisting of F, Cl, Br, I.

13. A pharmaceutical composition comprising an amount of active agent effective to modulate cellular proliferation and a pharmaceutically acceptable carrier, said active agent being selected from the group consisting of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising an amount of active agent effective to inhibit protein kinases and a pharmaceutically acceptable carrier, said active agent being selected from the group consisting of a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof.

15. A compound selected from the group consisting of:















































; and



;

or a pharmaceutically acceptable salt of such compound.